title: Stereospecific reduction of a potent kinesin spindle protein (KSP) inhibitor in human tissues.
abstract: Compound A, 1-{(3R,3aR)-3-[3-(4-acetylpiperazin-1-yl)propyl]-7-fluoro-3-phenyl-3a,4-dihydro-3H-pyrazolo[5,1-c][1,4]benzoxazin-2-yl}ethanone, is a novel and potent inhibitor of the mitotic kinesin spindle protein. Metabolism studies with human hepatocytes showed that Compound A underwent significant ketone reduction to its biologically active metabolite M1. Here, we describe the studies that characterized the metabolic interconversion between Compound A and M1 in vitro in human tissues. LC-MS/MS analysis showed that the ketone reduction was stereospecific for M1 with no diastereomer of M1 detected in incubations with human hepatocytes. Interestingly, such stereospecific ketone reduction was not observed with Compound B, the enantiomer of Compound A. No reductive products were observed when Compound B was incubated with human hepatocytes. Studies with human liver subcellular fractions showed that Compound A was reduced to M1 primarily by human liver cytosol with little contribution from human liver microsomes and mitochondria. NADPH was the preferred cofactor for the reduction reaction. Reverse oxidation of M1 back to Compound A was also observed, preferentially in human liver cytosol with NADP(+) as the cofactor. The interconversion between Compound A and M1 in human liver cytosol was inhibited significantly by flufenamic acid and phenolphthalein (potent inhibitors for aldo-keto reductase 1Cs, p<0.05), but not by menadione, a selective inhibitor for carbonyl reductase. In addition to the liver, S9 from human lung and kidney was also capable of catalyzing this interconversion. Collectively, the results implicated the aldo-keto reductase 1Cs as the most likely enzymes responsible for the metabolic interconversion of Compound A and its active metabolite M1.
authors.affiliation: Department of Drug Metabolism and Pharmacokinetics, West Point, PA 19486, USA. chunze.li@pfizer.com
authors.forename: Chunze
authors.initials: C
authors.lastname: Li
authors.forename: Bing
authors.initials: B
authors.lastname: Lu
authors.forename: Robert M
authors.initials: RM
authors.lastname: Garbaccio
authors.forename: Edward S
authors.initials: ES
authors.lastname: Tasber
authors.forename: Mark E
authors.initials: ME
authors.lastname: Fraley
authors.forename: George D
authors.initials: GD
authors.lastname: Hartman
authors.forename: Jingjing
authors.initials: J
authors.lastname: Ye
authors.forename: Jane C
authors.initials: JC
authors.lastname: Harrelson
authors.forename: Thomayant
authors.initials: T
authors.lastname: Prueksaritanont
mesh_terms: D048588:Benzoxazines / Q000494:pharmacology*; D002478:Cells, Cultured; D002851:Chromatography, High Pressure Liquid; D022781:Hepatocytes / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D007668:Kidney / Q000187:drug effects / Q000378:metabolism; D016547:Kinesins / Q000037:antagonists & inhibitors*; D008168:Lung / Q000187:drug effects / Q000378:metabolism; D009249:NADP / Q000378:metabolism; D011720:Pyrazoles / Q000494:pharmacology*; D013237:Stereoisomerism; D013347:Subcellular Fractions / Q000187:drug effects / Q000378:metabolism
chemical_list: C548453:1-(3-(3-(4-acetylpiperazin-1-yl)propyl)-7-fluoro-3-phenyl-3a,4-dihydro-3H-pyrazolo(5,1-c)(1,4)benzoxazin-2-yl)ethanone; D048588:Benzoxazines; C470243:KIF11 protein, human; D011720:Pyrazoles; D009249:NADP; D016547:Kinesins